Aptose Biosciences Inc. Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments

Note 9 - Other Expenses

6 Months Ended

Jun. 30, 2018

9.	Other expenses

Components of research and development expenses:

	Three months ended June 30,				Six months ended June 30,
		2018		2017		2018		2017
Program costs, excluding salaries	$	2,201	$	692	$	4,476	$	1,939
Salaries		457		314		946		743
License fee, CrystalGenomics (note 9(a),(b))		5,000		-		5,000		-
Stock-based compensation		152		73		519		123
Depreciation and amortization		8		9		17		18
	$	7,818	$	1,088	$	10,958	$	2,823

May 7, 2018,

under the license agreement with CrystalGenomics the Company, the Company paid the option fee of

$2.0

million in cash to CrystalGenomics in order to exercise early the option and gain an exclusive license to develop and commercialize CG-

806

in all territories outside of Korea and China. Future milestone payments are described in note

10.

June 13, 2018,

the Company paid

$3.0

million in cash to CrystalGenomics to gain an exclusive license to develop and commercialize CG-

806

in China. Future milestone payments are described in note

10.

Components of general and administrative expenses:

	Three months ended June 30,				Six months ended June 30,
		2018		2017		2018		2017
General and administrative excluding salaries	$	1,003	$	560	$	2,296	$	1,268
Salaries		533		443		1,074		1,301
Stock-based payment financing fees (note 6(a)(iii)		600		-		600		-
Stock-based compensation		364		376		2,225		386
Depreciation and amortization		11		14		18		28
	$	2,511	$	1,393	$	6,213	$	2,983

Components of finance expense:

Components of finance income: